Nathan Hardy
Director of Finance/CFO at SANA BIOTECHNOLOGY, INC.
Net worth: 5 M $ as of 31/03/2024
Profile
Presently, Nathan Hardy holds the position of Chief Financial Officer & Senior Vice President at Sana Biotechnology, Inc. In his past career Mr. Hardy was Executive Director & Head-Corporate Finance at Amgen, Inc. and Vice President-Finance for Juno Therapeutics, Inc. Mr. Hardy received an undergraduate degree from the University of Utah and an MBA from the University of Notre Dame.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SANA BIOTECHNOLOGY, INC.
0.23% | 07/03/2024 | 511,250 ( 0.23% ) | 5 M $ | 31/03/2024 |
Nathan Hardy active positions
| Companies | Position | Start |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Director of Finance/CFO | 01/09/2018 |
Former positions of Nathan Hardy
| Companies | Position | End |
|---|---|---|
| JUNO THERAPEUTICS INC | Director of Finance/CFO | 01/06/2018 |
| AMGEN INC. | Director/Board Member | 01/08/2017 |
Training of Nathan Hardy
| University of Notre Dame | Masters Business Admin |
| University of Utah | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Nathan Hardy
